At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 342 enrolled
Drug / intervention
Ergoferon +1 moredrug
Likely dose
Ergoferon 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients
In Brief
A Phase 3 clinical trial evaluating Ergoferon and Placebo for Acute Upper Respiratory Tract Infections. Completed, enrolled 342 participants across 18 sites.
Detailed Summary
The purpose of this study is: * to evaluate safety of the liquid dosage form of Ergoferon in the treatment of acute upper respiratory tract infections in adults; * to evaluate clinical efficacy of the liquid dosage form of Ergoferon in the treatment of acute upper respiratory tract infections in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Upper Respiratory Tract Infections
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJan 2013
Primary CompletionDec 2014
Study CompletionApr 2015
TodayJul 2026
First PostedJan 10, 2013
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.5 years ago
Interventions
Ergoferondrug
5 ml 3 times a day
Placebodrug
5 ml 3 times a day